ATAI LIFE SCIENCES NV (9VC.DE) Stock Price, Quote, News and Overview
FRA:9VC - Deutsche Boerse Ag - NL0015000DX5 - Common Stock - Currency: EUR
9VC.DE Quote, Performance and Key Statistics
FRA:9VC (7/16/2025, 7:00:00 PM)
2.22
-0.08 (-3.52%)
The current stock price of 9VC.DE is 2.22 EUR. In the past month the price increased by 8.29%. In the past year, price increased by 34.22%.
9VC.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY.DE | ELI LILLY & CO | 57.12 | 643.14B | ||
| 1LLY.MI | ELI LILLY & CO | 56.94 | 641.15B | ||
| ZEG.DE | ASTRAZENECA PLC | 16.04 | 370.97B | ||
| JNJ.DE | JOHNSON & JOHNSON | 16.19 | 338.10B | ||
| 1JNJ.MI | JOHNSON & JOHNSON | 15.4 | 321.60B | ||
| NOV.DE | NOVO NORDISK A/S-B | 18.09 | 253.18B | ||
| RHO.DE | ROCHE HOLDING AG-BR | 14.48 | 236.30B | ||
| SAN.PA | SANOFI | 10.86 | 203.43B | ||
| SNW.DE | SANOFI | 10.86 | 203.40B | ||
| 1SAN.MI | SANOFI | 10.82 | 202.60B | ||
| NOT.DE | NOVARTIS AG-REG | 14.01 | 198.10B | ||
| 6MK.DE | MERCK & CO. INC. | 10.53 | 178.03B |
Related stock screener links
About 9VC.DE
Company Profile
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company. The company is headquartered in Berlin, Berlin and currently employs 54 full-time employees. The company went IPO on 2021-06-18. The firm engages in developing various treatments that focuses on various mental health disorders. The firm's therapeutic lead compound include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder.
Company Info
ATAI LIFE SCIENCES NV
Wallstrasse 16
Berlin BERLIN DE
Employees: 54
Phone: 498921539035
ATAI LIFE SCIENCES NV / 9VC.DE FAQ
What is the stock price of ATAI LIFE SCIENCES NV today?
The current stock price of 9VC.DE is 2.22 EUR. The price decreased by -3.52% in the last trading session.
What is the ticker symbol for ATAI LIFE SCIENCES NV stock?
The exchange symbol of ATAI LIFE SCIENCES NV is 9VC and it is listed on the Deutsche Boerse Ag exchange.
On which exchange is 9VC.DE stock listed?
9VC.DE stock is listed on the Deutsche Boerse Ag exchange.
What is the price forecast or stock price prediction for ATAI LIFE SCIENCES NV stock?
13 analysts have analysed 9VC.DE and the average price target is 7.63 EUR. This implies a price increase of 243.59% is expected in the next year compared to the current price of 2.22. Check the ATAI LIFE SCIENCES NV stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ATAI LIFE SCIENCES NV worth?
ATAI LIFE SCIENCES NV (9VC.DE) has a market capitalization of 470.95M EUR. This makes 9VC.DE a Small Cap stock.
How many employees does ATAI LIFE SCIENCES NV have?
ATAI LIFE SCIENCES NV (9VC.DE) currently has 54 employees.
What are the support and resistance levels for ATAI LIFE SCIENCES NV (9VC.DE) stock?
ATAI LIFE SCIENCES NV (9VC.DE) has a support level at 2.21 and a resistance level at 2.3. Check the full technical report for a detailed analysis of 9VC.DE support and resistance levels.
Is ATAI LIFE SCIENCES NV (9VC.DE) expected to grow?
The Revenue of ATAI LIFE SCIENCES NV (9VC.DE) is expected to grow by 184.92% in the next year. Check the estimates tab for more information on the 9VC.DE EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ATAI LIFE SCIENCES NV (9VC.DE) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of 9VC.DE, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of 9VC.DE, evaluating the profitability, health, valuation and growth aspects
- ATAI LIFE SCIENCES NV (9VC.DE) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ATAI LIFE SCIENCES NV (9VC.DE) Sales and EPS estimates to see what analysts future expectations are.
- ATAI LIFE SCIENCES NV (9VC.DE) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ATAI LIFE SCIENCES NV (9VC.DE) Insider and Institutional Ownership to learn about the owners and their transactions.
- ATAI LIFE SCIENCES NV (9VC.DE) Stock Chart to make your own analysis
- ATAI LIFE SCIENCES NV (9VC.DE) Latest news and press-releases to stay up to date.
Does ATAI LIFE SCIENCES NV (9VC.DE) stock pay dividends?
9VC.DE does not pay a dividend.
When does ATAI LIFE SCIENCES NV (9VC.DE) report earnings?
ATAI LIFE SCIENCES NV (9VC.DE) will report earnings on 2025-08-11, before the market open.
What is the Price/Earnings (PE) ratio of ATAI LIFE SCIENCES NV (9VC.DE)?
ATAI LIFE SCIENCES NV (9VC.DE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.79).
9VC.DE Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to 9VC.DE. When comparing the yearly performance of all stocks, 9VC.DE is one of the better performing stocks in the market, outperforming 97.2% of all stocks.
9VC.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to 9VC.DE. 9VC.DE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
9VC.DE Financial Highlights
Over the last trailing twelve months 9VC.DE reported a non-GAAP Earnings per Share(EPS) of -0.79. The EPS decreased by -264% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -76.24% | ||
| ROE | -98.17% | ||
| Debt/Equity | 0.06 |
9VC.DE Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to 9VC.DE. The Buy consensus is the average rating of analysts ratings from 13 analysts.
For the next year, analysts expect an EPS growth of 47.9% and a revenue growth 184.92% for 9VC.DE